Image
Interactive Professor

Clinical Updates on Congenital and Acquired Lipodystrophy

Translating Reseach Into Practice

Meeting Slides

Guidelines

The Clinical Approach to the Detection of Lipodystrophy—A Consensus Statement From the American Association of Clinical Endocrinologists

A consensus statement from the American Academy of Clinical Endocrinologists about the classification, detection, and diagnosis of various types of lipodystrophy. The expert task force of clinical practitioners and leaders in lipodystrophy research aims to increase awareness of these underdiagnosed disorders and provide a framework for future diagnostic criteria.
Handelsman Y, et al. Endocr Pract. 2013;19(1):107-116.

American Diabetes Association’s Standards of Medical Care in Diabetes—2014 

The American Diabetes Association’s Standards of Care provide clinicians, patients, researchers, payers, and other interested individuals with the components of good diabetes management, general treatment goals, and tools to evaluate the quality of care. Importantly, these recommendations should be adjusted based on individual preferences, comorbidities, and other patient-related factors.
American Diabetes Association. Diabetes Care. 2014;37(suppl 1):S14-S80.

American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013

This algorithm from the AACE outlines a complications-centric approach to diabetes care and recommendations on evidence-based treatment approaches. The document contains sections on managing obesity, prediabetes, hyperglycemia, hypertension, and hyperlipidemia, as well as other risk-reduction strategies.
Garber AJ, et al. Endocr Pract. 2013;19(2):327-336.

Tools

Lipodystrophy Resource Center at The Endocrine Society

The Endocrine Society has created a variety of educational materials covering the pathophysiology, clinical presentations, and treatment of lipodystrophies. Particular emphasis is placed on the connections between generalized or partial adipose tissue loss and their often severe metabolic complications, including severe insulin resistance, type 2 diabetes, and hypertriglyceridemia.

Lipodystrophy United Website

Lipodystrophy United is an organization of committed individuals living strong with Lipodystrophy. Our mission is to provide an interactive community, facilitating support and education for anyone affected by this rare disease. We serve as a resource and to increase awareness in the general population as well as the medical and insurance communities. We advocate and act as a catalyst for new patient diagnosis by assisting healthcare professionals in the understanding of Lipodystrophy trends, physical attributes and clinical symptoms in order to aid in the advancement of knowledge, treatment and future research.

Lipodystrophy Connect Regisrty

Registry stores detailed information in one place making it easier for researchers to share and study information, while still protecting the privacy of those who take part. This research is being done to better understand LD, and to answer questions such as how LD is treated, and what can be done to improve care for people with LD.

Suggested Readings

Ectopic lipid storage and insulin resistance: a harmful relationship.

Borén J, et al. J Intern Med. 2013;274(1):25-40.

Clinical classification and treatment of congenital and acquired lipodystrophy.

Chan JL, Oral EA. Endocr Pract. 2010;16(2):310-323.

Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

Chan JL, et al. Endocr Pract. 2011;17(6):922-932.

Lipodystrophy: pathophysiology and advances in treatment.

Fiorenza CG, et al. Nat Rev Endocrinol. 2011;7(3):137-150.

Lipodystrophies: genetic and acquired body fat disorders.

Garg A. J Clin Endocrinol Metab. 2011;96(11):3313-3325.

Lipodystrophy: metabolic insights from a rare disorder.

Huang-Doran I, et al. J Endocrinol. 2010;207(3):245-255.

Leptin and the central nervous system control of glucose metabolism.

Morton GJ, Schwartz MW. Physiol Rev. 2011;91(2):389-411.

Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies.

Nolis T. J Hum Genet. 2014;59(1):16-23.

Rationale for leptin-replacement therapy for severe lipodystrophy.

Oral EA, Chan JL. Endocr Pract. 2010;16(2):324-333.

How to diagnose a lipodystrophy syndrome.

Vantyghem MC, et al. Ann Endocrinol (Paris). 2012;73(3):170-189.

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice